EntryPoint Capital’s Benitec Biopharma BNTC Stock Holding History

EntryPoint Capital’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$259K	Buy	+24,322	New	+$282K	0.08%	530

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

EntryPoint Capital's BNTC Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Benitec Biopharma (BNTC) in Q1 2026: 24,322 shares worth $259K. The stake represents 0.08% of the portfolio and ranks #530 among its holdings.

88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

EntryPoint Capital held 24,322 shares of Benitec Biopharma worth $259K as of Q1 2026.
Benitec Biopharma was a new EntryPoint Capital position in Q1 2026.
Benitec Biopharma made up 0.08% of EntryPoint Capital's portfolio in Q1 2026, its #530 holding.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.